Fish oil
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Fish Oil (Omega-3 Fatty Acids: EPA and DHA) |
| Overview | |
| FDA Approval | No (Used as a dietary supplement; not specifically FDA-approved for cancer treatment) |
| Used for | Investigational use in cancer treatment for potential cytotoxic effects and enhancement of chemotherapy and radiation therapy efficacy |
| Clinical Trial Phase | Clinical trials (e.g., advanced cancer study with cachexia, metastatic breast cancer Phase II trial, advanced non-small cell lung cancer trial) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Well-tolerated; potential side effects include fishy aftertaste, gastrointestinal discomfort |
| OS without | Malnourished advanced cancer patients: 110 days; adequately nourished patients: 350 days; chemotherapy alone in non-small cell lung cancer: 39% one-year survival |
| OS with | Fish oil supplementation: Malnourished advanced cancer patients: 210 days; adequately nourished patients: 500 days; metastatic breast cancer trial with high-DHA: median survival of 34 months vs. low-DHA: 18 months; non-small cell lung cancer with fish oil: 60% one-year survivalProperty "Has OS with" (as page type) with input value "Fish oil supplementation: Malnourished advanced cancer patients: 210 days; adequately nourished patients: 500 days; metastatic breast cancer trial with high-DHA: median survival of 34 months vs. low-DHA: 18 months; non-small cell lung cancer with fish oil: 60% one-year survival" contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process. |
| PFS without | Not specified |
| PFS with | Not specifically documented; research highlights increased survival and potential for enhanced treatment efficacy |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Omega-3 fatty acids, EPA and DHA, from fish oil have shown anti-cancer properties in both lab and clinical settings, including apoptosis induction and chemotherapy/radiation enhancement. Clinical trials indicate fish oil increases survival times and reduces chemotherapy toxicity in patients with advanced cancers, suggesting a beneficial role in cancer therapy. The data underscore the need for additional research to establish efficacy, optimal dosing, and integration into conventional cancer treatment protocols.
From Ben Williams Book: Not specified
Loading comments...
